Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma
- PMID: 37982732
- DOI: 10.1080/17474086.2023.2285978
Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma
Keywords: CD20/CD3; DLBCL; bispecific antibodies; epcoritamab; glofitamab.